Gastric cancer (GC) is one of the most prevalent malignant types in the world and an
aggressive disease with a poor 5-year survival. This cancer is biologically and genetically …

Context: ERBB2 (erb-b2 receptor tyrosine kinase 2 or HER2) is currently the only biomarker
established for selection of a specific therapy for patients with advanced gastroesophageal …

There is an urgent need for first-line treatment options for patients with human epidermal
growth factor receptor 2 (HER2)-negative, locally advanced unresectable or metastatic …

Gastric cancer is the third leading cause of cancer-related deaths worldwide. Over 95% of
gastric cancers are adenocarcinomas, which are typically classified based on anatomic …

Background First-line chemotherapy for advanced or metastatic human epidermal growth
factor receptor 2 (HER2)-negative gastric or gastro-oesophageal junction adenocarcinoma …

Gastric cancer is the fifth most frequently diagnosed cancer and the third leading cause of
death from cancer in the world. Several advances have been made in the staging …

Background Antibody–drug conjugates have emerged as a powerful strategy in cancer
therapy and combine the ability of monoclonal antibodies to specifically target tumour cells …

Recent therapeutic advances in oncology have been driven by the identification of tumour
genotype variations between patients, called interpatient heterogeneity, that predict the …

Human epidermal growth factor receptor 2 (HER2) overexpression is increasingly
recognized as a frequent molecular abnormality in gastric and gastroesophageal cancer …

The NCCN Clinical Practice Guidelines in Oncology for Gastric Cancer provide evidence-
and consensus-based recommendations for a multidisciplinary approach for the …